Navigation Links
Zyngenia, Inc. Promotes Chief Scientific Officer and Hires Chief Business Officer
Date:12/12/2011

he many strategic and operational challenges associated with early-stage drug development.  From 2004 to 2005, he served as Vice President of Research and a member of the senior management team at Cellective Therapeutics, a start-up antibody company acquired by MedImmune, LLC in October 2005. Previously, Dr. Hilbert spent eight years at Human Genome Sciences most recently as Vice President, Research guiding the preclinical development of antibodies and genomics-based therapeutics. He was instrumental in the transformation of the company from a genomics research company to an integrated drug development organization. Prior to joining HGS, Dr. Hilbert was a Staff Fellow in the National Cancer Institute of the National Institutes of Health. He received his B.S. from Haverford College and his Ph.D. from the University of Pennsylvania.

Appointment of Daniel L. Menichella

Prior to joining Zyngenia, Mr. Menichella was the Senior Vice President of Corporate Development and Strategy at Talecris Biotherapeutics from October 2007 to September 2011.  At Talecris, Mr. Menichella led corporate strategy, licensing and acquisition activities and was actively involved in both Talecris' initial public offering and eventual sale to Grifols S.A. of Barcelona Spain in June 2011 for $3.4 billion.  Prior to Talecris, Mr. Menichella served in various capacities related to business development, strategic planning and alliance management at Merck KGaA, the global pharmaceutical and chemical company, from December 2002 until October 2007. Over the course of his five years at Merck KGaA, Mr. Menichella served as Vice President, Business Development; Vice President, Corporate Strategic Planning; and Vice President, Corporate Business Development and Alliance Management. He also played an integral role in Merck's €10.6 billion purchase of Serono; the biotech firm headquartered in Geneva Switzerland and was active in the integration following the transact
'/>"/>

SOURCE Zyngenia, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zyngenia, Inc. Raises $10 Million in Series A Funding
2. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
3. WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry
4. AMDL, Inc. Promotes CFO Akio Ariura to Chief Operating Officer and Expands Management Team
5. BioMed Realty Trust Promotes Kent Griffin to President
6. Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area
7. BioStorage Technologies, Inc. Promotes Lori Ball to Senior Vice President and Expands Role
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Pathway for Biosimilars Act Protects Patients, Promotes Competition, Preserves Innovation and Creates Quality Jobs, Lilly Says
10. Ratcliff Promotes Jorge Burbano to Senior Associate; Tess Kavanagh and Tony Keung to Associate
11. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... , , NEW YORK, Dec. 15 ... is available in its catalogue: , The ... 2015, Pipeline Analysis and Reimbursement , ... , The author has released its latest research "The ...
... , WILMINGTON, Del. and CHARLOTTESVILLE, Va., ... and the University of Virginia (UVa) in Charlottesville, today ... collaboration to enhance development of new treatments primarily for ... peripheral vascular disease (PAD). , (Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ...
... 15 The Mosaic Company (NYSE: MOS ) plans to ... tables on Tuesday, January 5, 2010, after the close of trading ... on Mosaic,s website at mosaicco.com/investors. , The Company will ... 2010, to discuss the results. The call will begin at ...
Cached Biology Technology:Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 2Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 3Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 4Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 5Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 6Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 7Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 8Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 9Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 10Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 11Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 12Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 13Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 14Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 15Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 16Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 17Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement 18AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 2AstraZeneca and the University of Virginia Sign Strategic Research Collaboration to Develop Novel Treatments for Cardiovascular Disease 3Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... 22, 2015 Research and Markets ( ... "Global Wearable Technologies Market and Applications, Opportunities, ... and Forecast 2014-2020" report to their offering. ... devices that can be worn on the user,s ...
(Date:12/22/2014)... (NASDAQ: NXTD and NXTDW) ("NXT-ID" or the ... commerce market, announces it has retained famous pickpocket, entertainer and ... CES debut of the Wocket™ biometric smart wallet.  ... booth January 6th and 7 th , 2015, demonstrating some ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4
... Insect Technique (SIT), the release of sexually sterile male insects ... to the problem of malaria in Africa. A new supplement, ... reviews the history of the technique, and features details about ... The supplement, edited by Dr Mark Benedict, who along with ...
... Researchers from the universities of Bristol and St. Andrews in ... skin affects how healthy and therefore attractive they appear, and ... most desirable complexion. The work will be published in the ... Using specialist computer software, a total of 54 ...
... , , SANTA ANA, ... ( SCMM, Prime Standard: SMY), a leading provider of solutions ... results for its third quarter ended September 30, 2009. In ... Corporation, revenue more than doubled, reflecting the success of the ...
Cached Biology News:Are sterile mosquitoes the answer to malaria elimination? 2Skin color gives clues to health 2SCM Microsystems Reports Third Quarter 2009 Results 2SCM Microsystems Reports Third Quarter 2009 Results 3SCM Microsystems Reports Third Quarter 2009 Results 4SCM Microsystems Reports Third Quarter 2009 Results 5SCM Microsystems Reports Third Quarter 2009 Results 6SCM Microsystems Reports Third Quarter 2009 Results 7SCM Microsystems Reports Third Quarter 2009 Results 8SCM Microsystems Reports Third Quarter 2009 Results 9SCM Microsystems Reports Third Quarter 2009 Results 10SCM Microsystems Reports Third Quarter 2009 Results 11SCM Microsystems Reports Third Quarter 2009 Results 12